Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

James Larkin

United Kingdom

Research Interests

Explore related searches

Articles (20)

Collaborators (6)

Ricky Thakrar

University College London

UNITED KINGDOM

Thomas Powles

Professor of Genitourinary Oncology

Queen Mary University of London

UNITED KINGDOM

Antonio José Rullán

University College London

UNITED KINGDOM

Andrew Tutt

Professor of Clinical Oncology

Institute of Cancer Research

UNITED KINGDOM

Fiona Byrne

The Francis Crick Institute

UNITED KINGDOM

Bart Neyns

Vrije Universiteit Brussel

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

James Larkin

Research Interests

Explore related searches

Articles (20)

Collaborators (6)

Ricky Thakrar

Thomas Powles

Antonio José Rullán

Andrew Tutt

Fiona Byrne

Bart Neyns

Make your next move.

James Larkin

Research Interests

Explore related searches

Articles (20)

71 Integrated spatial multi-omics reveals tumour immune microenvironment programmes underlying durable response and resistance to dual ICI therapy in ccRCC

Somatic evolution following cancer treatment in normal tissue.

Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases

Evaluating the potential of candidate surrogate endpoints for overall survival in treatment-naive metastatic melanoma treated with anti-PD-1-based regimens with or without anti-CTLA-4 therapy.

Relationships Between Plasma KIM-1 Levels, Peripheral Immune Profiles and Disease-Free Survival Outcomes in the TransRAMPART Study

KIM-1 in Advanced Papillary and Clear Cell Renal Cell Carcinoma.

10-Years of First-Line Ipilimumab and Nivolumab in Advanced Melanoma: A Single Centre Experience.

Durvalumab monotherapy versus active monitoring for resected primary renal cell carcinoma in RAMPART: An international, phase 3, randomized controlled trial.

BNT326-01: A Phase 1b/2 trial of BNT326/YL202 (HER3 ADC) as monotherapy and in combination with pumitamig (anti-PD-L1 × VEGF bsAb) in patients with advanced solid tumors.

Long-term efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO plus RELA) versus NIVO plus ipilimumab (NIVO plus IPI) in advanced melanoma: An updated indirect treatment comparison (ITC) with 5-year follow-up data

Long-term survivorship rates among previously treated advanced melanoma patients achieving objective response (OR) with lifileucel.

Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing.

Efficacy and safety of stereotactic radiosurgery in the management of brain metastases in patients with metastatic melanoma.

CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer.

The cost-effectiveness of tumour-infiltrating lymphocyte cell therapy for advanced melanoma: a systematic review.

Circulating tumor DNA (ctDNA) analysis in participants (pts) with advanced clear cell renal cell carcinoma (ccRCC) treated with first-line pembrolizumab (pembro) monotherapy from the phase 2 KEYNOTE-427 study.

Efficacy and safety of avelumab plus axitinib vs sunitinib in patients (pts) with very favorable-risk advanced renal cell carcinoma (aRCC): Subgroup analysis from the JAVELIN Renal 101 trial

Patient-reported outcomes in resected renal cell carcinoma: Active monitoring vs. durvalumab and tremelimumab in the RAMPART trial.

Peripheral blood correlates of outcomes with adjuvant tremelimumab plus durvalumab for patients with renal cell carcinoma at high or intermediate risk of relapse: Initial results from the TransRAMPART study.

Ipilimumab and Nivolumab in Renal Cell Carcinoma: Real-World Experience in Rare Variant Renal Cell Carcinoma, Brain Metastases and Impact of Immune-Related Adverse Events and Steroid Use.

Collaborators (6)

Ricky Thakrar

Thomas Powles

Antonio José Rullán

Andrew Tutt

Fiona Byrne

Bart Neyns

Make your next move.